MG
BMRN icon

Mather Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mather Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.2K Buy
1,367
+1,004
+277% +$55K ﹤0.01% 998
2026
Q1 		$20.5K Buy
+363
New +$21.2K ﹤0.01% 1272
2025
Q2 		– Sell
-14
Closed -$990 – 742
2025
Q1 		$990 Buy
14
+11
+367% +$740 ﹤0.01% 1642
2024
Q4 		$197 Sell
3
-17
-85% -$1.14K ﹤0.01% 1700
2024
Q3 		$1.41K Sell
20
-9
-31% -$752 ﹤0.01% 1526
2024
Q2 		$2.53K Buy
29
+13
+81% +$1.08K ﹤0.01% 1823
2024
Q1 		$1.54K Buy
+16
New +$1.43K ﹤0.01% 1578

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Mather Group's BMRN Position: Q2 2026 in Review

Mather Group increased its BioMarin Pharmaceuticals (BMRN) stake by 277% in Q2 2026, buying an estimated $55K and bringing the position to 1,367 shares worth $78.2K. The position accounts for ﹤0.01% of the portfolio, ranked #998.

Mather Group first reported a position in BMRN in Q1 2024 and has held it in 7 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Mather Group held 1,367 shares of BioMarin Pharmaceuticals worth $78.2K as of Q2 2026.
  • Mather Group bought 1,004 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $55K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #998 holding.
  • Mather Group first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.